Mitochondrial Dysfunction and Nanocarrier-Based Treatments in Chronic Obstructive Pulmonary Disease (COPD)
Mitochondrial dysfunction significantly contributes to the pathogenesis and progression of chronic obstructive pulmonary disease (COPD). To treat mitochondrial dysfunction in COPD, novel drug delivery systems (DDS) are needed. In this review, we provide a brief overview of the current understanding...
Main Authors: | Kiyoshi Sato, Hiroyoshi Kawakami |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-11-01
|
Series: | Oxygen |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-9801/3/4/26 |
Similar Items
-
Chronic obstructive pulmonary disease (COPD) and erectile dysfunction (ED): Results of the BRED observational study
by: Stefano Lauretti, et al.
Published: (2016-10-01) -
New treatment options for a patient with chronic heart failure and chronic obstructive pulmonary disease
by: M. E. Statsenko, et al.
Published: (2022-04-01) -
Erectile dysfunction in male patients with severe chronic obstructive pulmonary disease
by: Hamdy M Hasan, et al.
Published: (2017-01-01) -
Prevalence of thyroid dysfunction in chronic obstructive pulmonary disease patients in a tertiary care center in North India
by: Shyam Chand Chaudhary, et al.
Published: (2018-01-01) -
Proteome Profiling of Lung Tissues in Chronic Obstructive Pulmonary Disease (COPD): Platelet and Macrophage Dysfunction Contribute to the Pathogenesis of COPD
by: Liu Y, et al.
Published: (2020-05-01)